BCSG1 基因在乳腺癌新辅助化疗疗效评估中的价值-深圳市第二人民医院乳腺疾病诊疗中心.docVIP

BCSG1基因在乳腺癌新辅助化疗疗效评估中的价值 何劲松1,袁建辉2,王先明1,郭良峰1,朱国献1,伍健春1,李戎1,王敏1,陈伟财1,吴恢升1 （1.深圳市第二人民医院乳腺疾病诊疗中心 深圳 518035；2.深圳市疾病预防控制中心 深圳 518020） 摘要： 目的 探讨乳腺癌特异基因（BCSG1）在乳腺癌新辅助化疗疗效评估中的价值。方法 采用免疫组化SP法和荧光定量PCR方法检测36例乳腺癌患者新辅助化疗(CEF方案)前后乳腺癌组织BCSG1的表达情况，比较化疗前后肿瘤体积的变化情况，分析新辅助化疗前后BCSG1蛋白表达与肿瘤形态学变化的关系。结果 36例乳腺癌患者新辅助化疗后肿瘤体积均有明显缩小（P0.01），病灶缓解率(CR+PR)为85.6%；新辅助化疗后BCSG1 mRNA表达水平亦明显低于化疗前（P0.05），BCSG1蛋白高表达率低于新辅助化疗前（P0.01）。结论 乳腺癌新辅助化疗后BCSG1在分子和蛋白水平均明显降低，与新辅助化疗后肿瘤缩小呈正相关，提示BCSG1可作为乳腺癌新辅助化疗疗效的预测因子。 关键词 乳腺癌特异基因（BCSG1）； 乳腺癌； 新辅助化疗 Importance of BCSG1 on Evaluating the Curative Effect of Neoadjuvant Chemotherapy to Breast Cancer He Jinsong, Wang Xianming, Yuan Jianhui, et al. The Center of Diagnosis and Treat to Breast Disease, The Second Hospital of Shenzhen City, Shenzhen, 518035, Guangdong Province China. Abstract：Objective　To discuss the importance of BCSG1 on evaluating the curative effect of neoadjuvant chemotherapy to breast cancer. Methods　 The expressions of BCSG1 of cancer was assayed by immunohistochemistry and RT-PCR in 36 cases of breast cancer patients before and after receiving neoadjuvant chemotherapy of CEF (Cyclophosphamide, Epirubicin and Fluorouracil) regimen. The therapeutic response of neoadjuvant chemotherapy was evaluated by the morphological and pathological observation. The relationship between expressions of BCSG1 and morphological response to neoadjuvant chemotherapy was analyzed. Results　 Among the cases studied, the diameter of tumor shrunk to be smaller（P0.01）and the improved rate of the focus (CR+PR) was 85.6%..The expression of BCSG1 mRNA （P0.05）and the high expression rate of BCSG1（P0.01）were decreased significantly after receiving neoadjuvant chemotherapy. Conclusion After neoadjuvant chemotherapy ,the expression of BCSG1 mRNA and protein could be decreased significantly,which was positive relation to morphological response of the morphological response tumor. BCSG1 can be a prognosticate gene which evaluate the effect of neoadjuvant chemotherapy to breast